All news

UBS lifts CME price target to $310, keeps Neutral

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

UBS raised its CME Group price target to $310 from $270 while keeping a Neutral rating, citing solid third-quarter earnings with strong revenue growth and an EPS beat, plus progress on single stock futures and Treasury Link. JPMorgan separately upgraded CME to Overweight with a $367 target.

Read original source

CME company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.